Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11851260 | PMC |
| http://dx.doi.org/10.1111/jdv.20236 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Superoxide Dismutase in the Treatment of Vitiligo: A Systematic Review.
Cureus
July 2025
Dermatology, Centro Dermatológico "Dr. Ladislao de la Pascua", IMSS para el Bienestar, Mexico City, MEX.
Vitiligo is a chronic autoimmune skin condition characterized by the progressive loss of melanocytes, resulting in well-defined hypopigmented or achromic patches. Oxidative stress is believed to play a role in its pathogenesis, and superoxide dismutase (SOD), an antioxidant enzyme, has emerged as a potential therapeutic option. This systematic review aimed to evaluate the efficacy of oral or topical SOD, used either alone or in combination with other interventions, in the treatment of vitiligo.
View Article and Find Full Text PDFVitiligo is a common pigment disorder of the skin resulting in destruction of melanocytes. Non-segmental vitiligo (NSV) is an autoimmune disorder. The etiopathogenesis of segmental vitiligo (SV) remains incompletely understood.
View Article and Find Full Text PDFClinical Prognostic Factors Predicting Outcomes in Vitiligo: A Scoping Review.
Pigment Cell Melanoma Res
September 2025
Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
The progression of non-segmental vitiligo is highly unpredictable, exhibiting various phenotypes that can range from rapid progression to stability. Due to limited literature, we conducted a scoping review to identify factors influencing the outcomes of non-segmental vitiligo, focusing on disease progression, extent, and response to therapy. This review adhered to PRISMA-ScR guidelines and involved searching the PubMed and Google Scholar databases for studies published in English from January 1995 to December 2023.
View Article and Find Full Text PDFComparative Efficacy of Topical Tofacitinib versus Topical Tacrolimus in the Treatment of localized Vitiligo: A Randomized, Investigator-Blinded, Intraindividual Trial.
Br J Dermatol
August 2025
Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Background: Topical ruxolitinib was recently approved by the US FDA for vitiligo. Studies comparing other topical Janus kinase inhibitors with established topical therapies like tacrolimus are lacking.
Objectives: To compare the efficacy and tolerability of topical tofacitinib and topical tacrolimus in patients with localized vitiligo using patient-reported and investigator-reported outcome measures.
Vogt-Koyanagi-Harada Disease in which Poliosis and Alopecia Occurred after a Long Period of Time.
Acta Dermatovenerol Croat
December 2024
Shiro Niiyama, MD, PhD, Department of Dermatology, Toho University Ohashi Medical Center, 2-22-36 Ohashi, Meguro-ku, Tokyo 153-8515 Japan;
Vogt-Koyanagi-Harada (VKH) disease is a multisystem autoimmune disorder affecting melanocyte-containing tissues such as the eyes, ears, central nervous system, and skin. A 55-year-old Japanese male presented with an 8-week history of increasing diffuse hair loss. A physical examination revealed diffuse alopecia of the scalp.
View Article and Find Full Text PDF